share_log

The Analyst Landscape: 5 Takes On TScan Therapeutics

The Analyst Landscape: 5 Takes On TScan Therapeutics

分析師視角:對TScan Therapeutics的5個看法
Benzinga ·  12/11 22:01
Ratings for TScan Therapeutics (NASDAQ:TCRX) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
在過去三個月中,5位分析師對TScan Therapeutics(納斯達克:TCRX)的評級展示了看好和看淡的不同觀點。
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
下表提供了他們近期評級的彙總視圖,展示了過去30天的情緒變化,並將其與前幾個月進行了比較。
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $12.6, a high estimate of $15.00, and a low estimate of $11.00. Holding firm without variation, the current average remains at the previous average price target.
分析師通過對12個月價格目標的評估提供更深入的見解,顯示平均目標爲12.6美元,高估爲15.00美元,低估爲11.00美元。 當前平均值保持不變,仍然是之前的平均價格目標。
Investigating Analyst Ratings: An Elaborate Study
分析師評級的調查:一項詳盡的研究
The standing of TScan Therapeutics among...
通過對最近分...
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論